Precision BioSciences, Inc (DTIL)

Etorro trading 970x250
Precision BioSciences, Inc (DTIL) Logo

About Precision BioSciences, Inc

Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome editing platform to cure genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, which is in Phase 1/2a clinical trial, an allogeneic anti-CD19 CAR T cell product candidate for the patients with relapsed or refractory, or R/R, non-Hodgkin lymphoma, or NHL, or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; and PBCAR20A, that is in Phase 1/2a clinical trial, an allogeneic anti-CD20 CAR T therapy for the treatment NHL, chronic lymphocytic leukemia, and small lymphocytic lymphoma, as well as developing PBCAR269A, which is in Phase 1/2a clinical trial, an allogeneic anti-BCMA CAR T cell product candidate for the treatment of R/R multiple myeloma. The Food segment develops food and nutrition products; and provides technology-centric solutions, Elo life systems, and Elo’s technology platform solutions. The company has development and commercial license agreement with Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina. Address: 302 East Pettigrew Street, Durham, NC, United States, 27701

Precision BioSciences, Inc News and around…

Latest news about Precision BioSciences, Inc (DTIL) common stock and company :

Aligos (ALGS) Stock Down on Hepatitis Drug Development Halt
07 Jan, 2022 Yahoo! Finance

Aligos Therapeutics' (ALGS) phase I study evaluating its chronic hepatitis B candidate, ALG-010133, did not achieve sufficient activity against the disease.

Lilly (LLY) Inks Deal for Multiple Neurologic Indications
07 Jan, 2022 Yahoo! Finance

Eli Lilly (LLY) partners with Entos Pharmaceuticals to expand its pipeline in multiple neurologic indications.

Biogen (BIIB) Opts for In-Licensing SMA Therapy From Ionis
05 Jan, 2022 Yahoo! Finance

Biogen (BIIB) exercises its option to acquire a royalty-bearing license from Ionis to develop and commercialize BIIB115/ION306 for treating spinal muscular atrophy.

Stocks That Hit 52-Week Lows On Wednesday
05 Jan, 2022 FinancialContent

Before 10 am on Wednesday, 99 companies set new 52-week lows. Facts of Interest About Today's 52-Week Lows: Sea ...

Precision BioSciences to Present at the 40th Annual J.P. Morgan Health Care Conference
04 Jan, 2022 FinancialContent

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing ex vivo allogeneic CAR T therapies and in vivo therapies with its ARCUS® genome editing platform, today announced that Michael Amoroso, Chief Executive Officer will present a corporate update at the Annual J.P. Morgan Health Care Conference taking place virtually January 10-13, 2022. Precision Co-Founder and Chief Scientific Officer, Derek Jantz, Ph.D., Chief Financial Officer, Alex Kelly and Chief Medical Officer, Alan List, M.D., will join Michael for Q&A.

Intellia's (NTLA) CRISPR Therapies Show Promise Amid Competition
31 Dec, 2021 Yahoo! Finance

While Intellia's (NTLA) pipeline is in early-stage clinical studies, its development is progressing well. Collaborations are a primary source of revenues in the absence of a marketed product.

Can-Fite (CANF) Files Patent Applications for Namodenoson
30 Dec, 2021 Yahoo! Finance

Can-Fite (CANF) files patent applications in several countries for treating all advanced solid tumors. The filing comes after Can-Fite's drug cleared all tumor lesions in advanced liver cancer.

The Math Shows LABU Can Go To $68
30 Dec, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Daily S&P Biotech Bull 3X Shares ETF (LABU), we found that the implied analyst target price for the ETF based upon its underlying holdings is $68.09 per unit.

Pluristem (PSTI) Misses Study Goal to Treat COVID-Related ARDS
28 Dec, 2021 Yahoo! Finance

Pluristem's (PSTI) phase II studies evaluating PLX-PAD cells for treating acute respiratory distress syndrome associated with COVID-19 fail to achieve the primary endpoint.

Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ...
28 Dec, 2021 Yahoo! Finance

Cambridge, MA, based Investment company Opaleye Management Inc. (Current Portfolio) buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics Pharmaceuticals Inc, Amicus Therapeutics Inc, Merus NV, sells ESSA Pharma Inc, Seres Therapeutics Inc, CM Life Sciences Inc, Lumos Pharma Inc, Kezar Life Sciences Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Opaleye Management Inc..

Precision BioSciences Completes Spin-Out of Elo Life Systems
21 Dec, 2021 FinancialContent

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing ex vivo allogeneic CAR T therapies and in vivo therapies with its ARCUS® genome editing platform, today announced that it has entered into an agreement with a syndicate of investors led by ACCELR8 to separate its wholly owned Elo Life Systems subsidiary and create an independent food and agriculture business.

Bellus (BLU) Stock Surges on Data From Chronic Cough Study
14 Dec, 2021 Yahoo! Finance

Bellus Health (BLU) achieves the primary endpoint in a phase IIb study evaluating BLU-5937 for the treatment of refractory chronic cough.

Intellia (NTLA) Begins Dosing in Hereditary Angioedema Study
14 Dec, 2021 Yahoo! Finance

Intellia (NTLA) doses the first patient in a phase I/II study to evaluate NTLA-2002 as a single-dose therapy for preventing attacks in patients having hereditary angioedema.

SpringWorks (SWTX) & AbbVie Unite for Multiple Myeloma Drug
13 Dec, 2021 Yahoo! Finance

SpringWorks Therapeutics (SWTX) collaborates with AbbVie (ABBV) to evaluate the combination of nirogacestat with AbbVie's ABBV-383 for relapsed or refractory multiple myeloma.

Precision BioSciences Reports Clinical Program Updates for Its Allogeneic CAR T Pipeline
11 Dec, 2021 FinancialContent

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced program updates across its allogeneic CAR T cell therapy pipeline, including updated data for its Phase 1/2a clinical study of PBCAR0191 with enhanced lymphodepletion (eLD)1 presented at the 63rd American Society of Hematology (ASH) Annual Meeting.

Affimed (AFMD) Starts AFM24-102 Study With Roche's Tecentriq
09 Dec, 2021 Yahoo! Finance

Affimed (AFMD) starts recruiting patients in a phase I/IIa study to evaluate the combination of AFM24 and Roche's atezolizumab in solid tumors.

Precision BioSciences to Host Virtual Webcast and Conference Call to Review Interim Phase 1/2a PBCAR0191 CAR T Data and Provide CAR T Program Updates on Saturday, December 11, 2021
06 Dec, 2021 FinancialContent

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced it will review interim data results presented at the 63rd American Society of Hematology Annual Meeting from the PBCAR0191 CD19 allogeneic CAR T program and provide other CAR T program updates during a company-hosted webcast and conference call on Saturday, December 11, 2021 at 7:30 PM ET.

Bayer's (BAYRY) Phase III Study on Nubeqa Combo Meets Goal
06 Dec, 2021 Yahoo! Finance

Bayer's (BAYRY) phase III study evaluating Nubeqa in combination with docetaxel and androgen deprivation therapy for treating metastatic hormone-sensitive prostate cancer meets the primary endpoint.

Merck's (MRK) Keytruda Gets FDA Nod for Expanded Melanoma Use
06 Dec, 2021 Yahoo! Finance

Post FDA approval, Merck's (MRK) anti-PD-1 therapy Keytruda is now approved as an adjuvant treatment for adult & pediatric patients with stage IIB, IIC or III melanoma following complete resection.

The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
06 Dec, 2021 FinancialContent

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt ...

Precision BioSciences to Present Preclinical Gene Editing Data on its ARCUS-Based Chronic Hepatitis B Program at the HEP DART 2021 Conference
03 Dec, 2021 FinancialContent

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced it will present preclinical data for its chronic hepatitis B virus (HBV) program at the HEP DART 2021 conference taking place in Cabo San Lucas, Mexico, December 5 – 9, 2021.

Adagene (ADAG) Gets FDA Nod to Begin Solid Tumor Antibody Study
30 Nov, 2021 Yahoo! Finance

The FDA grants Adagene (ADAG) a clearance to initiate clinical studies of its investigational candidate ADG116 in combination with pembrolizumab to treat advanced/metastatic solid tumors.

Novavax (NVAX) Stock Up YTD on COVID-19 Vaccine Potential
29 Nov, 2021 Yahoo! Finance

Novavax (NVAX) is likely to generate huge revenues as the company has started filing approvals for emergency use of its COVID-19 vaccine in multiple nations.

12 Health Care Stocks Moving In Thursday's After-Market Session
18 Nov, 2021 FinancialContent

Gainers NeuroOne Medical Tech (NASDAQ:NMTC) stock moved upwards by 6.47% to $2.63 during Thursday's after-market session. The ...

Precision BioSciences Earnings Perspective: Return On Capital Employed
11 Nov, 2021 FinancialContent

Benzinga Pro data, Precision BioSciences (NASDAQ:DTIL) reported Q3 sales of $24.04 million. Earnings fell to a loss of $11.27 million, ...

Precision BioSciences Reports Third Quarter 2021 Financial Results and Provides Business Update
10 Nov, 2021 FinancialContent

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the third quarter ended September 30, 2021 and provided a business update.

Precision BioSciences Earnings Preview
09 Nov, 2021 FinancialContent

Precision BioSciences (NASDAQ:DTIL) is set to give its latest quarterly earnings report on Wednesday, 2021-11-10. Here's what investors ...

Precision BioSciences to Highlight Capabilities of ARCUS Gene Editing for Allogeneic CAR T Cell Immunotherapies at The Society for Immunotherapy of Cancer 36th Annual Meeting
09 Nov, 2021 FinancialContent

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced that the abstract titled, “Allogeneic CAR T cells with Deoxycytidine Kinase Knockdown Demonstrate Resistance to Fludarabine” has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting taking place November 10 – 14, 2021 in Washington, D.C.

Precision BioSciences Appoints Sam Wadsworth, Ph.D. and Shari Lisa Piré, J.D. to Board of Directors
08 Nov, 2021 FinancialContent

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced that Sam Wadsworth, Ph.D., Chief Scientific Officer of Ultragenyx Gene Therapy, an operating unit of Ultragenyx Pharmaceutical Inc., and Shari Lisa Piré, J.D., Chief Legal & Sustainability Officer at Plume Design, have been appointed to the Company’s Board of Directors.

Precision BioSciences Announces Two Oral Presentations Highlighting Updated Interim Data from Lead PBCAR0191 CAR T Immunotherapy for Relapsed and Refractory B-cell Malignancies at the 63rd Annual Meet
04 Nov, 2021 FinancialContent

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced that investigators involved with the Phase 1/2a study of PBCAR0191 in Relapsed/Refractory (R/R) non-Hodgkin’s lymphoma (NHL) and B-cell acute lymphoblastic leukemia (B-ALL), will present new data during two oral presentations at the 63rd Annual Meeting of the American Society of Hematology (ASH) taking place December 11-14, 2021.

Precision BioSciences, Inc (DTIL) is a NASDAQ Common Stock listed in , ,

970x250